Provided by Tiger Trade Technology Pte. Ltd.

Cue Biopharma, Inc.

23.98
-0.6300-2.56%
Post-market: 24.400.4200+1.75%19:30 EDT
Volume:177.75K
Turnover:4.28M
Market Cap:174.20M
PE:-0.81
High:26.00
Open:25.55
Low:23.24
Close:24.61
52wk High:45.50
52wk Low:4.97
Shares:7.26M
Float Shares:6.81M
Volume Ratio:0.84
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.4600
EPS(LYR):-8.4244
ROE:-1603.48%
ROA:-172.66%
PB:75.41
PE(LYR):-2.85

Loading ...

Cue Biopharma appoints Shao-Lee Lin as CEO

TIPRANKS
·
May 01

Cue Biopharma Announces $30 Million Private Placement

THOMSON REUTERS
·
May 01

Cue Biopharma Inc - to Pay $15 Mln Upfront, up to $676.5 Mln in Milestones for Ascendant-221

THOMSON REUTERS
·
May 01

Cue Biopharma Inc - Plans Global Phase 2B Trial in Food Allergy After 2H 2026

THOMSON REUTERS
·
May 01

Cue Biopharma Expands Pipeline With Exclusive License From Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-Ige Antibody

THOMSON REUTERS
·
May 01

Press Release: Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

Dow Jones
·
May 01

Cue Biopharma trading halted, volatility trading pause

TIPRANKS
·
Apr 28

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:47 AM

Reuters
·
Apr 28

Cue Biopharma trading halted, volatility trading pause

TIPRANKS
·
Apr 27

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM

Reuters
·
Apr 27

NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:30 AM

Reuters
·
Apr 24

Cue Biopharma trading halted, news pending

TIPRANKS
·
Apr 24

Cue Biopharma implements 1-for-30 reverse stock split

Reuters
·
Apr 22

Cue Biopharma Announces 1-for-30 Reverse Stock Split

THOMSON REUTERS
·
Apr 22

Cue Biopharma to present new preclinical data on CUE-401 at IMMUNOLOGY2026

Reuters
·
Apr 15

Cue Biopharma shareholders approved reverse stock split proposal at annual meeting

Reuters
·
Apr 14

Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim deal

Reuters
·
Apr 08

Cue Biopharma Inc - Eligible for up to $337.5 Mln in Additional Milestone Payments and Royalties

THOMSON REUTERS
·
Apr 08

Cue Biopharma Inc - Expects to Receive $7.5 Mln Payment in May 2026

THOMSON REUTERS
·
Apr 08

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment From Boehringer Ingelheim Collaboration and License Agreement

THOMSON REUTERS
·
Apr 08